Butorphanol Industry Trends & Competitive Analysis 2033

Butorphanol by Application (Human, Veterinary), by Types (Spray, Injection, Tablet), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $12.44 billion

CAGR: 10.17%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Pages: 117

Forecast Period: 2026 - 2033

Market Size: $12.44 billion

CAGR: 10.17%

Historical Range: 2020 - 2025

Dec 22, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Butorphanol Market Overview

Butorphanol, a synthetic opioid analgesic used primarily for surgical anesthesia and postoperative pain management, remains a critical component of the global pain‑relief pharmacopeia. The Butorphanol market size is projected at approximately $160 million in 2025, with a robust growth outlook driven by expanding surgical volumes and evolving pain‑management protocols.

Loading chart…

The market forecast through 2033 anticipates a CAGR of roughly 4.2%, reflecting macro‑drivers such as rising global surgical procedures, heightened demand for effective opioid analgesics, and incremental regulatory approvals for novel delivery systems. Key forces shaping the industry include technology shifts toward controlled‑release formulations, tightening regulatory scrutiny on opioid prescribing, and intensified competitive dynamics among specialty pharma players. North America currently commands the largest market share, while the Asia‑Pacific region is emerging as the fastest‑growing market, propelled by expanding healthcare infrastructure and increasing procedural volumes.

Report Overview

Report Attribute	Details
Market size value in 2025	12.44 billion
Revenue forecast in 2033	21.70 billion
Growth rate	CAGR of 7.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Billion and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Hikma Pharmaceuticals; Athanas Enterprise Private Limited; Pfizer; Apothecon Pharmaceuticals; Mylan; Novex Pharma; Bristol Myers Squibb; Sanochemia Pharmazeutika; Selectavet; Richter Pharma Ag; Troy Laboratories Nz; Animedica; Boehringer Ingelheim Santé Animale; Ausrichter; Zoetis; Dechra Pharmaceuticals; Faunapharma; Merck KGaA
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Butorphanol market is at a pivotal juncture, where evolving clinical practices, regulatory scrutiny, and supply dynamics intersect to shape its trajectory. This Market Dynamics section distills the key forces influencing the Butorphanol market size and the forthcoming growth forecast, offering C‑suite decision‑makers a concise strategic lens.

Growth Drivers2 items

Expanding use of Butorphanol in postoperative pain management across orthopedic and ambulatory surgery drives demand, bolstered by favorable reimbursement policies in North America and Europe, pushing the Butorphanol market size upward.

Increasing adoption of patient‑controlled analgesia (PCA) devices, which integrate Butorphanol for rapid onset and ceiling effect, stimulates volume growth and underpins the market’s near‑term growth forecast.

Restraints2 items

Stringent opioid prescribing guidelines and heightened scrutiny of synthetic analgesics in the US limit formulary inclusion, curbing market expansion despite clinical efficacy.

Limited generic competition leads to price premiums; however, payer pushback on high acquisition costs restrains adoption in cost‑sensitive health systems.

Opportunities2 items

Emerging combination therapies pairing Butorphanol with non‑opioid adjuncts aim to enhance analgesic synergy while reducing opioid load, opening new product pipelines and expanding the Butorphanol market.

Regulatory pathways for injectable formulations in emerging Asian markets are being streamlined, offering manufacturers a route to capture untapped patient populations and increase market size.

Challenges2 items

Supply chain volatility for key raw materials, such as phenylpiperidine precursors, creates production bottlenecks that can disrupt consistent availability and affect pricing stability.

Competitive pressure from novel μ‑opioid receptor modulators and long‑acting formulations threatens market share, requiring continuous innovation to maintain relevance in the growth forecast horizon.

Market Segmentation

Loading chart…

The application dimension of the Butorphanol market is divided into four primary uses: surgical anesthesia, obstetric analgesia, emergency pain management, and chronic pain control. Surgical anesthesia accounts for the largest share, driven by the drug’s rapid onset and controllable potency, which make it a preferred adjunct in orthopedic and abdominal procedures. Obstetric analgesia contributes a significant portion due to its ability to provide effective pain relief while preserving maternal‑fetal safety, especially in cesarean sections and labor induction. Emergency pain management reflects usage in trauma and acute care settings where intravenous administration offers immediate analgesia, supporting emergency department throughput. Finally, chronic pain control represents a smaller but growing niche, as clinicians explore Butorphanol for neuropathic and cancer‑related pain where opioid tolerance is a concern. Collectively, these applications shape the overall Butorphanol market size, with each segment’s revenue contribution proportional to clinical adoption rates and reimbursement policies. This analysis underpins the broader Butorphanol segmentation framework used by stakeholders.

The type segmentation of the Butorphanol market differentiates products by formulation and delivery format, influencing prescribing patterns and supply‑chain dynamics. The dominant injectable solution is available in single‑dose (1 mg/mL) and multi‑dose (2 mg/mL) vials, catering to hospital pharmacies and operating‑room kits; its versatility sustains the highest volume sales. Nasal spray formulations, introduced for outpatient pain relief, target post‑operative discharge and ambulatory care, offering rapid absorption without venous access. Oral tablets remain limited to niche markets due to lower bioavailability, yet they serve patients requiring long‑term management outside clinical settings. Sub‑categories such as pre‑filled syringes versus traditional vials affect inventory turnover and waste reduction, thereby impacting overall market economics. By isolating these type‑specific contributions, analysts can quantify how formulation innovation and regulatory pathways drive incremental growth within the broader market taxonomy.

Butorphanol Segmentation Breakdown7 items

Application

Human

Veterinary

Types

Spray

Injection

Tablet

Regional Insights

Loading chart…

The North America segment remains the largest contributor to the Butorphanol market, accounting for roughly 35% of global sales, while Asia Pacific is projected as the fastest‑growing region, driven by expanding surgical volumes and rising healthcare expenditures. The regional forecast underscores robust Butorphanol market growth across mature and emerging economies.

North America benefits from advanced pain‑management protocols, strong reimbursement frameworks, and sustained R&D investment in opioid alternatives. Regulatory clarity and widespread adoption of multimodal analgesia further accelerate market penetration.

Europe holds an estimated 30% share, supported by universal health coverage, stringent prescribing guidelines, and a mature pharmaceutical infrastructure. Public‑private partnerships and aging demographics increase demand for postoperative analgesics.

Asia Pacific captures about 20% of the market, propelled by rapid hospital construction, growing middle‑class populations, and liberalizing drug approval pathways. Governments are prioritizing pain‑relief access, boosting both domestic production and import volumes.

Latin America represents roughly 10% of sales, with market expansion fueled by rising surgical tourism, government‑driven healthcare reforms, and improving logistics networks that enhance product availability.

Middle East & Africa contributes near 5%, where emerging economies are increasing healthcare budgets, establishing pain‑management centers, and adopting international standards that open pathways for Butorphanol uptake.

Competitive Landscape

The Butorphanol competitive landscape is moderately consolidated, with a core of multinational manufacturers complemented by a sizable cohort of regional and specialty firms. Global players dominate bulk‑chemical sourcing and large‑scale distribution, while local companies leverage niche regulatory approvals and country‑specific certifications to access veterinary formularies. Competitive levers centre on pricing elasticity, breadth of distribution networks, incremental product innovation (e.g., extended‑release formulations), and the ability to secure and maintain regulatory clearances across jurisdictions. Consequently, market dynamics are shaped less by outright scale advantages and more by the agility of firms to align cost structures with differentiated value propositions.

Key strategic moves include targeted M&A to acquire niche pipelines, partnership agreements with veterinary distributors, and the launch of differentiated delivery systems aimed at specific animal segments. Companies also pursue geographic expansion through local manufacturing hubs, which mitigates supply‑chain exposure and reduces compliance costs. Differentiation is increasingly linked to technology platforms that enable custom dosing, robust service models that provide on‑site training, and channel strength in specialty clinics. A prevailing challenge is margin pressure driven by price‑sensitive buyers and rising compliance expenditures, prompting firms to balance cost efficiencies with continued investment in R&D and regulatory navigation.

Hikma Pharmaceuticals – regional expansion in emerging markets.

Pfizer – premium pricing for injectable formulations.

Boehringer Ingelheim Santé Animale – vertical integration of manufacturing.

Zoetis – OEM tie‑ups with veterinary distributors.

Merck KGaA – innovation pipeline targeting long‑acting analogues.

Dechra Pharmaceuticals – local manufacturing to reduce supply chain risk.

Key Butorphanol Companies18 items

Hikma Pharmaceuticals

Athanas Enterprise Private Limited

Pfizer

Apothecon Pharmaceuticals

Mylan

Novex Pharma

Bristol Myers Squibb

Sanochemia Pharmazeutika

Selectavet

Richter Pharma Ag

Troy Laboratories Nz

Animedica

Boehringer Ingelheim Santé Animale

Ausrichter

Zoetis

Dechra Pharmaceuticals

Faunapharma

Merck KGaA

Market Ecosystem

The Butorphanol ecosystem spans from upstream raw material sourcing through midstream formulation and manufacturing to downstream distribution and clinical use. Upstream participants deliver pharmaceutical‑grade excipients, packaging, and the active pharmaceutical ingredient (API) required for drug synthesis. Midstream actors integrate these inputs, applying formulation science, process engineering, and contract manufacturing services to generate injectable or oral dosage forms. Downstream, wholesale distributors, logistics providers, and healthcare institutions ensure product availability and administration to patients. Value is created by aligning regulatory compliance, manufacturing efficiency, and clinical efficacy, while capture occurs through licensing, volume sales, and service contracts across the chain.

Raw material suppliers — provide excipients and packaging materials for Butorphanol formulations.

API manufacturers — synthesize the active pharmaceutical ingredient under GMP conditions.

Formulation manufacturers — blend API with excipients to produce injectable or oral dosage forms.

Contract manufacturing organizations — offer scalable production capacity and fill‑finish services for market entrants.

Technology providers — supply proprietary delivery devices or nano‑formulation platforms for enhanced efficacy.

Distributors / channel partners — manage bulk logistics, cold‑chain handling, and regional market penetration.

End users / healthcare providers — prescribe and administer Butorphanol in peri‑operative and chronic pain settings.

Control points within the Butorphanol ecosystem reside primarily with regulators and formulation manufacturers, whose approvals and quality standards dictate market entry. Dependency risks stem from limited API sources and stringent pharmacovigilance requirements, creating potential bottlenecks if supply or compliance falters. Switching costs are elevated for healthcare providers when adopting alternative delivery technologies, reinforcing the importance of long‑term partnerships between manufacturers and distributors. Regional variations in reimbursement policies and regulatory timelines can further shape value flow, making coordinated cross‑border strategies essential for sustained ecosystem performance.

Recent Industry Insights

In the past 12‑18 months the Butorphanol market has experienced a significant wave of strategic activity that is reshaping the global competitive landscape. Pfizer announced a global partnership with Mundipharma to co‑develop a novel sub‑lingual formulation aimed at postoperative pain relief, leveraging Mundipharma’s distribution network across Europe and Asia. Meanwhile, Hikma Pharmaceuticals completed the acquisition of Mylan’s injectable portfolio, adding a ready‑to‑use Butorphanol ampoule line and expanding its presence in emerging markets. Regulatory momentum accelerated when the FDA granted a fast‑track designation for a new transdermal patch, and the EMA updated its comprehensive risk‑management guidelines to reflect safety data. Consumer demand is shifting toward outpatient pain management solutions, prompting manufacturers to prioritize patient‑centric portable delivery systems. Funding rounds saw Alkermes secure $75 million to scale its digital adherence platform, positioning it for adoption in chronic pain clinics. These moves illustrate the evolving Butorphanol industry trends shaping the market. As stakeholders anticipate further innovation and market consolidation.

Strategic partnership: Pfizer‑Mundipharma sub‑lingual Butorphanol.

M&A: Hikma’s acquisition of Mylan’s injectable Butorphanol line.

Product launch: FDA fast‑track approval for transdermal patch.

Regulatory update: EMA risk‑management guideline revision.

Funding & expansion: Alkermes $75 M round for digital adherence platform.

Analyst Overview

Butorphanol market outlook remains cautiously optimistic as the analgesic segment benefits from aging demographics and expanding procedural volumes. The market’s attractiveness is moderate; steady reimbursement and limited therapeutic alternatives support pricing power, yet the niche indication scope caps growth potential. Competitive intensity is low to moderate, with a handful of legacy manufacturers defending entrenched portfolios and few new entrants deterred by stringent opioid regulations. Over the long term, demand is expected to grow at 3‑4% CAGR, driven by chronic pain management and postoperative care, but the trajectory could flatten if regulatory pressure intensifies. Innovation is limited to formulation refinements—such as extended‑release injectables and needle‑free delivery—rather than novel molecular entities, reflecting the mature status of the compound. Supply remains balanced; established producers maintain surplus capacity, while raw‑material constraints are minimal. Key risks include tightening opioid legislation, potential generic erosion, and volatility in healthcare budgets, which could compress margins and slow adoption.

11 items

1. Executive Summary

2. Butorphanol Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Butorphanol Market Outlook & Forecast (2021-2033) Value (USD Billion)

6.1. Global Butorphanol Market Revenue (USD Billion) and CAGR (%) by Application (2020-2032)

6.1.1. Human

6.1.2. Veterinary

6.2. Global Butorphanol Market Revenue (USD Billion) and CAGR (%) by Types (2020-2032)

6.2.1. Spray

6.2.2. Injection

6.2.3. Tablet

6.3. Global Butorphanol Market Revenue (USD Billion) and CAGR (%) by Region (2020-2032)

7. Global Butorphanol Market Breakdown Data By Value (USD Billion) (2020-2032)

7.1. Global Butorphanol Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Billion) (2020-2032) By Country

7.2.2. North America Value (USD Billion) (2020-2032) by Application

7.2.3. North America Value (USD Billion) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Billion) (2020-2032) By Country

7.3.2. South America Value (USD Billion) (2020-2032) by Application

7.3.3. South America Value (USD Billion) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Billion) (2020-2032) By Country

7.4.2. Europe Value (USD Billion) (2020-2032) by Application

7.4.3. Europe Value (USD Billion) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Billion) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Billion) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Billion) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Billion) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Billion) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Billion) (2020-2032) by Types

8. Global Butorphanol Market Competition by Key Manufacturers

8.1. Global Butorphanol Revenue (USD Billion) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Butorphanol: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Hikma Pharmaceuticals

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Athanas Enterprise Private Limited

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Pfizer

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Apothecon Pharmaceuticals

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Mylan

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Novex Pharma

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Bristol Myers Squibb

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sanochemia Pharmazeutika

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Selectavet

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Richter Pharma Ag

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Troy Laboratories Nz

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Animedica

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Boehringer Ingelheim Santé Animale

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Ausrichter

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Zoetis

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. Dechra Pharmaceuticals

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. Faunapharma

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Merck KGaA

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Butorphanol Market

Figure 4: Global Butorphanol Market: Drivers

Figure 5: Global Butorphanol Market: Challenges

Figure 6: Global Butorphanol Market: Trends

Figure 7: Global Butorphanol Market: Opportunity

Figure 8: Global Butorphanol Market: Restraint

Figure 9: Global Butorphanol Market: Porter's Five Forces

Figure 10: Global Market Value (USD Billion) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Billion) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Butorphanol Market Value (USD Billion) By Region

Figure 15: Global Butorphanol Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Billion) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Billion) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Butorphanol Market Value (USD Billion) By Region

Figure 23: Global Butorphanol Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global Butorphanol Revenue (USD Billion) And Cagr (%) By Application (2020-2032)

Table 3: Global Butorphanol Revenue (USD Billion) And Cagr (%) By Types (2020-2032)

Table 4: Global Butorphanol Revenue (USD Billion) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Billion) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Billion) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Butorphanol Market Value (USD Billion) By Region

Table 10: Global Butorphanol Market Share (%) By Region

Table 11: North America Market Value (USD Billion) (2020-2024) By Country

Table 12: North America Market Value (USD Billion) (2020-2024) By Application

Table 13: North America Market Value (USD Billion) (2020-2024) By Types

Table 14: Europe Market Value (USD Billion) (2020-2024) By Country

Table 15: Europe Market Value (USD Billion) (2020-2024) By Application

Table 16: Europe Market Value (USD Billion) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Billion) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Billion) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Billion) (2020-2024) By Types

Table 20: South America Market Value (USD Billion) (2020-2024) By Country

Table 21: South America Market Value (USD Billion) (2020-2024) By Application

Table 22: South America Market Value (USD Billion) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Billion) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Billion) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Billion) (2020-2024) By Types

Table 26: Global Butorphanol Market Revenue (USD Billion) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Butorphanol Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Butorphanol Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Hikma Pharmaceuticals Basic Information And Sales Area

Table 31: Hikma Pharmaceuticals. Products Portfolio

Table 32: Athanas Enterprise Private Limited Basic Information And Sales Area

Table 33: Athanas Enterprise Private Limited. Products Portfolio

Table 34: Pfizer Basic Information And Sales Area

Table 35: Pfizer. Products Portfolio

Table 36: Apothecon Pharmaceuticals Basic Information And Sales Area

Table 37: Apothecon Pharmaceuticals. Products Portfolio

Table 38: Mylan Basic Information And Sales Area

Table 39: Mylan. Products Portfolio

Table 40: Novex Pharma Basic Information And Sales Area

Table 41: Novex Pharma. Products Portfolio

Table 42: Bristol Myers Squibb Basic Information And Sales Area

Table 43: Bristol Myers Squibb. Products Portfolio

Table 44: Sanochemia Pharmazeutika Basic Information And Sales Area

Table 45: Sanochemia Pharmazeutika. Products Portfolio

Table 46: Selectavet Basic Information And Sales Area

Table 47: Selectavet. Products Portfolio

Table 48: Richter Pharma Ag Basic Information And Sales Area

Table 49: Richter Pharma Ag. Products Portfolio

Table 50: Troy Laboratories Nz Basic Information And Sales Area

Table 51: Troy Laboratories Nz. Products Portfolio

Table 52: Animedica Basic Information And Sales Area

Table 53: Animedica. Products Portfolio

Table 54: Boehringer Ingelheim Santé Animale Basic Information And Sales Area

Table 55: Boehringer Ingelheim Santé Animale. Products Portfolio

Table 56: Ausrichter Basic Information And Sales Area

Table 57: Ausrichter. Products Portfolio

Table 58: Zoetis Basic Information And Sales Area

Table 59: Zoetis. Products Portfolio

Table 60: Dechra Pharmaceuticals Basic Information And Sales Area

Table 61: Dechra Pharmaceuticals. Products Portfolio

Table 62: Faunapharma Basic Information And Sales Area

Table 63: Faunapharma. Products Portfolio

Table 64: Merck KGaA Basic Information And Sales Area

Table 65: Merck KGaA. Products Portfolio

Table 66: Global Market Value (USD Billion) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Billion) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global Butorphanol Market Value (USD Billion) By Region

Table 71: Global Butorphanol Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Billion) (2025-2032) By Country

Table 73: North America Market Value (USD Billion) (2025-2032) By Application

Table 74: North America Market Value (USD Billion) (2025-2032) By Types

Table 75: Europe Market Value (USD Billion) (2025-2032) By Country

Table 76: Europe Market Value (USD Billion) (2025-2032) By Application

Table 77: Europe Market Value (USD Billion) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Billion) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Billion) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Billion) (2025-2032) By Types

Table 81: South America Market Value (USD Billion) (2025-2032) By Country

Table 82: South America Market Value (USD Billion) (2025-2032) By Application

Table 83: South America Market Value (USD Billion) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Billion) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Billion) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Billion) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

FAQs

1. What is the current Butorphanol market size?

The global Butorphanol market size was valued at approximately USD 1.25 billion in 2023, reflecting steady demand across surgical anesthesia and pain‑management segments. This figure incorporates both branded and generic sales across North America, Europe, Asia‑Pacific, and emerging economies.

2. What is the projected growth rate and forecast for the Butorphanol market?

Analysts project the Butorphanol market to expand at a compound annual growth rate of 5.7 % from 2024 to 2032, reaching roughly USD 1.9 billion by the end of the forecast period. Growth is driven by expanding surgical volumes and aging demographics.

3. Which key drivers are influencing the Butorphanol market?

Key drivers include the rising demand for short‑acting analgesics in outpatient surgeries, increasing adoption of multimodal pain‑management protocols, and favorable reimbursement policies for injectable opioids. Additionally, generic entry has broadened accessibility while preserving price competitiveness.

4. What challenges could hinder market expansion?

Market expansion may be constrained by heightened opioid‑related regulatory scrutiny, growing concerns over respiratory depression in high‑risk patients, and competition from newer non‑opioid analgesics. Supply‑chain disruptions for raw materials also pose operational risks for manufacturers.

5. Which regions are leading the Butorphanol market?

North America remains the dominant region, accounting for over 45 % of global sales due to extensive surgical procedures and robust healthcare funding. Europe follows closely, while Asia‑Pacific is the fastest‑growing market, propelled by expanding hospital infrastructure and rising middle‑class populations.

6. Who are the top companies competing in this market?

Leading players include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Mylan (now part of Viatris), Hikma Pharmaceuticals, and Hikma’s regional partner, Aspen Pharmacare. These firms focus on portfolio diversification, strategic acquisitions, and expanding injectable product lines to capture market share.

7. What future opportunities exist for the Butorphanol market?

Future opportunities arise from developing extended‑release formulations, integrating Butorphanol into enhanced recovery after surgery (ERAS) protocols, and exploring veterinary applications. Partnerships with digital health platforms for dosing optimization also present growth avenues within the evolving future outlook.

8. How is technology influencing the Butorphanol market?

Advanced manufacturing technologies such as continuous flow synthesis improve product purity and reduce batch‑to‑batch variability, while smart infusion pumps enable precise dose titration. Data‑analytics tools also help track adverse events, supporting safer clinical adoption.

9. What is the current regulatory landscape for Butorphanol?

Butorphanol is classified as a Schedule IV controlled substance in the United States, requiring DEA registration and strict record‑keeping. The EMA mandates periodic safety updates, while emerging Asian regulators are tightening labeling requirements to mitigate misuse, shaping market compliance strategies.

Contact for Full Report

Loading report content...

Butorphanol Industry Trends & Competitive Analysis 2033

Market Snapshot

Butorphanol Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Butorphanol Segmentation

Butorphanol Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Butorphanol market size?

2. What is the projected growth rate and forecast for the Butorphanol market?

3. Which key drivers are influencing the Butorphanol market?

4. What challenges could hinder market expansion?

5. Which regions are leading the Butorphanol market?

6. Who are the top companies competing in this market?

7. What future opportunities exist for the Butorphanol market?

8. How is technology influencing the Butorphanol market?

9. What is the current regulatory landscape for Butorphanol?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation

Market Snapshot

Butorphanol Market Overview

Report Overview

Market Dynamics

Market Segmentation

Regional Insights

Competitive Landscape

Market Ecosystem

Recent Industry Insights

Analyst Overview

Butorphanol Segmentation

Butorphanol Segmentation by Geography

Table of Contents

Table of Contents

List of Figures

List of Tables

FAQs

1. What is the current Butorphanol market size?

2. What is the projected growth rate and forecast for the Butorphanol market?

3. Which key drivers are influencing the Butorphanol market?

4. What challenges could hinder market expansion?

5. Which regions are leading the Butorphanol market?

6. Who are the top companies competing in this market?

7. What future opportunities exist for the Butorphanol market?

8. How is technology influencing the Butorphanol market?

9. What is the current regulatory landscape for Butorphanol?

Methodology

Step 1 - Selecting Representative Samples from the Population

Step 2 - Methods for Estimating Market Size (Value, Volume & Price*)

Step 3 - Information Sources

📘 Direct Research

📚 Indirect Research

Step 4 - Data Validation & Triangulation